Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $31.82 ($492K) on 2026-02-02, disclosed to the SEC on 2026-02-04.
Scheduled sale ($492k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.82 | 957 | $30K | 6.2% |
| 2 | $32.87 | 14,043 | $462K | 93.8% |
| Total | $32.80 avg | 15,000 | $492K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |